Data to be presented at ASCO meeting (
Long-term follow-up data for TIBSOVO monotherapy in patients with IDH1-mutant conventional chondrosarcoma, a rare bone malignancy for which there are no approved systemic therapies.
Clinical and molecular characteristics for patients with relapsed/refractory IDH1-mutant AML with an exceptional response to TIBSOVO.
Abstracts being presented at ASCO are listed below (all times in Central Time) and are available online on the ASCO website here.
Abstract #7012: Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine
Date & Time:
Lead Author:
Abstract #11532: Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma
Date & Time:
Lead Author:
Abstract #7036: Clinical and molecular characteristics of AML patients with an exceptional response to ivosidenib
Date & Time:
Lead Author:
Additionally, at the EHA annual meeting in
Abstract #P490: Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine
Date & Time:
Session: Acute myeloid leukemia - Clinical
Lead Author:
Abstract #P441: Clinical and molecular characteristics of AML patients with an exceptional response to ivosidenib
Date & Time:
Session: Acute myeloid leukemia - Biology & translational research
Lead Author:
Abstract #P724: Updated substudy results for ivosidenib in IDH1-mutant relapsed/refractory myelodysplastic syndrome
Date & Time:
Session: Myelodysplastic syndromes - Clinical
Lead Author:
About TIBSOVO (ivosidenib tablets)
TIBSOVO is an oral targeted IDH1 inhibitor. The NMPA of
TIBSOVO is approved in the U.S.for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML): In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy
Relapsed or Refractory AML: For the treatment of adult patients with relapsed or refractory AML
Locally Advanced or Metastatic Cholangiocarcinoma: For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated
Tibsovo is also approved by the
About CStone
CStone (HKEX: 2616) is a biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Contact:
Tel: + 86-(0)512-8718-6550
(C) 2023 Electronic News Publishing, source